Company Overview of Actavis Pharma, Inc.
Actavis Pharma, Inc. develops, manufactures, and markets generic pharmaceutical products. It offers solid dosage and sterile dosage generic products. The company was formerly known as Schein Pharmaceutical, Inc. The company was founded in 1931 and is based in Parsippany, New Jersey. As of August 28, 2000, Actavis Pharma, Inc. operates as a subsidiary of Allergan plc.
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054
Founded in 1931
Key Executives for Actavis Pharma, Inc.
Senior Vice President of Strategic Development
Senior Vice President of Technical Operations
Compensation as of Fiscal Year 2015.
Actavis Pharma, Inc. Key Developments
Actavis Pharma, Inc. Wins $28.09 Million Federal Contract
Nov 11 15
Actavis Pharma Inc. has won a $28,088,035.50 federal contract modification from the U.S. Department of Veterans Affairs, Hines, Illinois, for clonidine patches.
Cipher Pharmaceuticals Inc., Ranbaxy Pharmaceuticals, Inc. and Galephar Pharmaceutical Research, Inc. Enters into Settlement Agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc
Oct 5 15
Cipher Pharmaceuticals Inc. along with its partners, Ranbaxy Pharmaceuticals, Inc. and Galephar Pharmaceutical Research, Inc. have entered into a settlement agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc. that dismisses the patent litigation suit relating to Actavis' Abbreviated New Drug Application (ANDA) for a generic version of Absorica (isotretinoin capsules). As part of the settlement agreement, Cipher, Ranbaxy and Galephar have entered into a non-exclusive license agreement with Actavis under which Actavis may begin selling its generic version of Absorica in the U.S. on December 27, 2020 (approximately nine months prior to the expiration of the patents in September 2021) or earlier under certain circumstances. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Orexigen Therapeutics, Inc. and Takeda Pharmaceuticals File Lawsuit against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc. and Actavis Inc. For Infringement of Contrave Patents
Jun 5 15
Orexigen Therapeutics, Inc. announced that it and its North American partner, Takeda Pharmaceuticals, have filed a lawsuit in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell generic versions of the currently approved doses of Contrave (naltrexone HCl /bupropion HCl extended release) tablets prior to the expiration of U.S. Patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. Takeda and Orexigen filed the lawsuit on the basis that Actavis' proposed generic products infringe each of these patents.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|